Survival Benefit of Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer: A Multi-institutional Case Control Study
about
Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal CarcinomatosisHyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: is there a role?Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional ControlCurrent status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer.Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score.Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI).Standard Clinical Protocol for Bidirectional Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Systemic Leucovorin, 5-Fluorouracil, and Heated Intraperitoneal Oxaliplatin in a Chloride-Containing Carrier Solution.
P2860
Q36387694-9304E8FB-68D6-4CEF-A369-6AB3713D126EQ36582197-0E73501D-CD22-455D-9F95-BC20F863C16BQ36884420-709E2ACE-6BEE-42FF-8E82-29DFE0CD561EQ38769834-A77A0B73-02CE-4B74-AA4E-9FD441617133Q38777716-644C2AD5-EDBB-4A18-B37D-9689A7F9AAA1Q40251231-A11895DA-8A98-44FF-9E97-6F464191FCC6Q40507435-1384F103-28DA-44AB-AF0C-08A02BD6B0FFQ48645092-FD8DD306-2C4A-43E3-8A69-39114A0BD0A0Q52952846-EFDBB8D5-A595-411D-9FA7-2C4FBD8EE62A
P2860
Survival Benefit of Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer: A Multi-institutional Case Control Study
description
im Mai 2014 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2014
@uk
name
Survival Benefit of Hypertherm ...... stitutional Case Control Study
@en
Survival Benefit of Hypertherm ...... stitutional Case Control Study
@nl
type
label
Survival Benefit of Hypertherm ...... stitutional Case Control Study
@en
Survival Benefit of Hypertherm ...... stitutional Case Control Study
@nl
prefLabel
Survival Benefit of Hypertherm ...... stitutional Case Control Study
@en
Survival Benefit of Hypertherm ...... stitutional Case Control Study
@nl
P2093
P2860
P1476
Survival Benefit of Hypertherm ...... stitutional Case Control Study
@en
P2093
Anne Sophie Oger
Dominique Berton-Rigaud
François Dravet
Frédéric Marchal
Gwenael Ferron
Gérard Lorimier
Isabelle Jaffre
Jean-François Le Brun
Jean-Marc Classe
P2860
P2888
P304
P356
10.1245/S10434-014-3693-7
P50
P577
2014-05-13T00:00:00Z
P6179
1046889631